Centuple Global Limited

BSE: CENTUPLE · Pharmaceuticals · sector

₹38.85BSE close 2026-10-26

Key numbers

Market cap₹62 cr

Price₹38.85

52w high / low₹64 / ₹28

P/E10.5xSector median 27.9x

P/B30.1xSector median 2.9x

Book value₹1.3

Dividend yield–Sector median 0.48%

ROE94.1%Sector median 11.7%

ROCE22.8%Sector median 12.3%

OPM0.4%Sector median 14.0%

Debt / equity3.26xSector median 0.16x

EV/EBITDA34.3xSector median 18.6x

Interest cover20,099.0x

Current ratio1.07x

Sales growth 3y+690.9%Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹0 cr vs borrowings ₹7 cr (FY26): borrowings are higher by ₹7 cr.
Operating profit covered interest 20,099.0x in the last 12 months.
Net loss in 2 of the last 6 quarters.
Other income was 0% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹38.85 on 2026-10-26: -39.1% from the 52-week high, +36.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹131.85 · low ₹9.81

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	0	12	109	174	279	0
EBITDA	0	0	2	1	-0	-0
OPM %	28.0%	0.8%	1.7%	0.4%	-0.1%	–
Other income	0	0	0	0	0	0
Net profit	0	0	1	1	-0	-0
EPS (₹)	0.12	0.16	2.42	1.05	0.18	0.04
Revenue YoY					+1,11,664.0%	-100.0%
Profit YoY					-900.0%	-300.0%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	2	1	1	0	574	562
EBITDA	-0	-0	0	0	2	2
Net profit	-0	-0	0	0	2	1
EPS (₹)	–	–	0.06	0.05	5.52	3.69
Revenue growth		-42.3%	-2.6%	-55.8%	+1,14,662.0%	–
Profit growth		–	–	0.0%	+4,933.3%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+690.9%	–	–
Net profit	–	–	–
EPS	–	–	–
Share price	–	– (2y)	–

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	1	2
Borrowings	0	7
Cash & equivalents	0	0
Total assets	1	343
Fixed assets	0	0
Capital work in progress	0	0
Investments	0	0
Receivables	0	338
Inventory	0	1
Payables	0	307

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	0	-28
Cash from investing	-0	0
Cash from financing	0	28
Capex	0	0
Free cash flow	0	-28

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	4.6%	73.0%
ROCE %	8.6%	25.9%
Debtor days	0	215
Inventory days	0	1
Payable days	0	197
Cash conversion cycle (days)	0	19
Working capital days	199	15

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
CENTUPLE	₹62 cr	10.5x	30.1x	94.1%	22.8%	0.4%	+690.9%	–

All 185 companies in Pharmaceuticals →

Business segments (2026-06-30)

Segment	Revenue	Share	EBIT	Margin
Tobacco Products	₹0 cr	–	₹0 cr	–
FMCG Products	₹0 cr	–	₹-0 cr	–

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	CENTUPLE
BSE code	531099
ISIN	INE396H01019
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.